S100A8/S100A9—also known as calprotectin or MRP8/14—is a calcium-binding protein complex predominantly released by activated neutrophils and monocytes during inflammatory responses. It is highly abundant at sites of acute inflammation and is particularly stable in stool, making it a powerful noninvasive biomarker for assessing gastrointestinal inflammatory activity. Elevated fecal S100A8/S100A9 levels are strongly associated with neoplastic and inflammatory diseases of the GI tract, including Crohn’s disease and ulcerative colitis, and correlate closely with histologic and endoscopic findings.
In research and clinical investigation, S100A8/S100A9 provides significant value in distinguishing chronic inflammatory bowel disease from non-inflammatory conditions such as irritable bowel syndrome, helping reduce unnecessary colonoscopies. Its performance surpasses traditional inflammatory markers like CRP, ESR, and hemoglobin for predicting disease relapse and monitoring disease severity. Compared with radiolabeled granulocyte tests—the former gold standard—it offers a safer, more practical alternative without radiation exposure, making it especially useful for pediatric and vulnerable populations.
Because elevated S100A8/S100A9 levels reflect acute inflammation and neutrophil activation, the biomarker is used to estimate the degree of gastrointestinal inflammation and supports research focused on inflammatory pathways, mucosal pathology, cancer screening strategies, and immune-driven disease processes.
This product is manufactured in USA by Immundiagnostik AG.
